IL1B and myocardial infarction: Canakinumab, an IL1‐β antagonist tested in CANTOS, a placebo controlled RCT, also has shown great promise and reported significant reductions in MACE rates as well as hs‐CRP levels amongst patients with a history of MI and baseline hs‐CRP levels ≥ 2 mg/L, irrespective of their revascularization status [81].